Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.
Department of Neurosurgery, Penn State Health, Hershey, Pennsylvania, USA,
Stereotact Funct Neurosurg. 2020;98(5):324-330. doi: 10.1159/000508541. Epub 2020 Aug 18.
Glossopharyngeal neuralgia (GPN) is a rare facial pain syndrome with debilitating symptoms. For medication-resistant GPN, stereotactic radiosurgery (SRS) is an emerging treatment option with a promising role; however, recurrence rates after SRS are fairly high. We present a patient who underwent repeat SRS for recurrent GPN and subsequently maintained over 3 years of complete pain relief. For the first time, we present a systematic review of repeat SRS for recurrent GPN.
Twelve cases of repeat SRS for GPN have previously been reported in the literature (13 studies including ours). Among patients with follow-up, initial pain relief was achieved in 83% (n = 10) of cases a median of 5 weeks after repeat SRS; 2 patients failed to obtain any pain relief. A favorable pain response (BNI I-IIIb) was achieved in 67 and 58% of cases at 6 and 12 months, respectively. All 13 were targeted to the glossopharyngeal meatus. Three patients (23%) experienced adverse radiation effects. Five patients (50%) experienced recurrence a median of 14 months after repeat SRS. Two patients (17%) required additional surgical intervention. At the final follow-up, 75% (n = 9) of the patients had a favorable pain outcome. Key Messages: Repeat SRS may be a viable alternative to open surgery for the treatment of recurrent GPN, albeit with an increased risk of adverse radiation effects. Though limited by a small cohort of patients, the best predictors of an effective second treatment may be a response to initial SRS for >5 months, a maximum dose >75 Gy, and a target at the glossopharyngeal meatus. Larger prospective studies are needed to better define its role.
舌咽神经痛(GPN)是一种罕见的面部疼痛综合征,其症状使人虚弱。对于药物难治性 GPN,立体定向放射外科(SRS)是一种新兴的治疗选择,具有很好的作用;然而,SRS 后的复发率相当高。我们报告了一例因复发性 GPN 而行重复 SRS 治疗的患者,随后患者维持了 3 年以上的完全缓解。这是首次系统地对复发性 GPN 进行重复 SRS 治疗的综述。
此前,文献中已有 12 例复发性 GPN 行重复 SRS 治疗的报道(包括我们的研究在内的 13 项研究)。在有随访的患者中,重复 SRS 后 5 周中位数时,83%(n=10)的患者最初疼痛缓解;2 例患者未获得任何疼痛缓解。6 个月和 12 个月时,分别有 67%和 58%的病例获得良好的疼痛反应(BNI I-IIIb)。13 例患者均以舌咽神经门为靶点。3 例患者(23%)出现不良放射效应。重复 SRS 后中位数 14 个月时,5 例患者(50%)复发。2 例患者(17%)需要额外的手术干预。最终随访时,75%(n=9)的患者疼痛结局良好。
重复 SRS 可能是治疗复发性 GPN 的一种可行替代方案,尽管有增加不良放射效应的风险。尽管患者数量较少,但首次 SRS 治疗>5 个月、最大剂量>75Gy 和以舌咽神经门为靶点可能是第二次治疗有效的最佳预测因素。需要更大规模的前瞻性研究来更好地确定其作用。